Nektar Therapeutics
NKTR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000906709
In the last 90 days, Nektar Therapeutics insiders filed 0 open-market purchases and 2 sales; 242 institutions reported holding it in 13F filings for Q3 2026, worth $2.17B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 14, 2026, 1:23 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $164.1M (297.1% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 12, 2026 | Mar 12, 2025 | Jan 10, 2024 | Jan 9, 2023 | Jan 11, 2022 |
| Revenue | $55.2M | $98.4M | $90.1M | $92.1M | $101.9M |
| Cost of revenue | $0 | $30.7M | $33.8M | $21.6M | $24.9M |
| Research and development | $117.3M | $120.9M | $114.2M | $218.3M | $400.3M |
| Selling, general and administrative | $68.7M | $76.8M | $77.4M | $92.3M | $122.8M |
| Operating income | -$140.1M | -$105.2M | -$263.7M | -$376.2M | -$446.1M |
| Interest expense | – | – | – | $0 | $0 |
| Income tax | -$138.0K | -$239.0K | -$200.0K | $3.21M | $557.0K |
| Net income | -$164.1M | -$119.0M | -$276.1M | -$368.2M | -$523.8M |
| EPS, basic | $-9.73 | $-0.58 | $-1.45 | $-1.97 | $-2.86 |
| EPS, diluted | $-9.73 | $-0.58 | $-1.45 | $-1.97 | $-2.86 |
| Weighted shares, basic | 16.9M | 205.7M | 190.0M | 187.1M | 183.3M |
| Weighted shares, diluted | 16.9M | 205.7M | 190.0M | 187.1M | 183.3M |
| Margins and growth | |||||
| Operating margin | -253.7% | -106.9% | -292.6% | -408.6% | -437.8% |
| Net margin | -297.1% | -120.9% | -306.3% | -400.0% | -514.0% |
| Revenue growth, year over year | −43.9% | +9.2% | −2.1% | −9.7% | −33.4% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 12, 2026 | Mar 12, 2025 | Jan 10, 2024 | Jan 9, 2023 | Jan 11, 2022 |
| Cash and equivalents | $15.1M | $44.3M | $35.3M | $88.2M | $25.2M |
| Accounts receivable | – | $0 | $1.21M | $5.98M | $22.5M |
| Inventory | $0 | $0 | $16.1M | $19.2M | $15.8M |
| Total current assets | $266.3M | $261.3M | $330.7M | $546.0M | $795.6M |
| Property, plant and equipment | $2.06M | $3.41M | $18.9M | $32.5M | $60.5M |
| Goodwill | – | – | $0 | $76.5M | $76.5M |
| Total assets | $280.4M | $303.9M | $398.0M | $710.6M | $1.12B |
| Accounts payable | $10.8M | $11.6M | $9.85M | $13.0M | $9.75M |
| Total current liabilities | $53.5M | $61.4M | $51.3M | $68.2M | $85.2M |
| Total liabilities | $190.6M | $243.1M | $267.0M | $344.0M | $437.7M |
| Shareholders' equity | $89.8M | $60.7M | $131.0M | $366.6M | $679.5M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 12, 2026 | Mar 12, 2025 | Jan 10, 2024 | Jan 9, 2023 | Jan 11, 2022 |
| Operating cash flow | -$208.5M | -$175.7M | -$192.6M | -$304.0M | -$412.7M |
| Capital expenditures | $171.0K | $1.47M | $865.0K | $5.68M | $15.0M |
| Free cash flow | -$208.7M | -$177.2M | -$193.5M | -$309.7M | -$427.6M |
| Depreciation and amortization | $1.03M | $4.10M | $7.00M | $12.2M | $13.0M |
| Stock-based compensation | $12.6M | $21.6M | $33.4M | $57.3M | $94.7M |
| Share buybacks | $0 | $3.00M | – | – | – |
| Investing cash flow | -$1.20M | $142.6M | $139.6M | $365.8M | $202.8M |
| Financing cash flow | $180.6M | $42.1M | $30.0K | $1.51M | $36.2M |
| Net change in cash | -$29.1M | $8.97M | -$53.0M | $63.0M | -$173.7M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 22.9% | 22.0% | 37.0% | 62.3% | 92.9% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 6, 2026 | 34.2M | +68.2% | SEC |
| Aug 7, 2026 | 34.1M | +79.5% | SEC |
| May 1, 2026 | 33.8M | −81.8% | SEC |
| Mar 11, 2026 | 28.7M | −84.6% | SEC |
| Oct 31, 2025 | 20.3M | −89.0% | SEC |
| Jul 31, 2025 | 19.0M | −89.7% | SEC |
| May 1, 2025 | 186.1M | +1.4% | SEC |
| Feb 27, 2025 | 186.1M | +1.4% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-15 in Q2 2025.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.